πŸ‡ΊπŸ‡Έ FDA
Patent

US 8673888

Depsipeptide for therapy of kidney cancer

granted A61KA61K38/15A61P

Quick answer

US patent 8673888 (Depsipeptide for therapy of kidney cancer) held by THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K38/15, A61P, A61P35/00